

Feb 18, 2015

08:30 am CET

Skanska to be construction partner for R&D center and corporate HQ for AstraZeneca, UK, for around GBP 300 M, about SEK 3.7 billion

Skanska has won a contract for the construction management of a research and development center and corporate headquarters for AstraZeneca in the UK. The contract is worth around GBP 300 M, about SEK 3.7 billion, which will be included the order in the order bookings for Skanska UK in the first quarter of 2015.

Work has started and is expected to be completed in 2017. The client will begin occupying the site at the end of 2016.

Skanska UK reported revenues of about SEK 15 billion in 2014. It has around 5,000 employees. The company is active in building and civil construction, utilities and building services, as well as facilities management and commercial development. In the UK, Skanska is a leader in public private partnerships, PPPs, also known as Privately Financed Initiatives, PFIs.

For further information please contact:

Direct line for media: tel: +46 (0)10-448 88 99

This and previous releases can also be found at www.skanska.com

Skanska AB may be required to disclose the information provided herein pursuant to the Securities Markets Act.

Skanska is one of the world's leading project development and construction groups with expertise in construction, development of commercial and residential premises, and public-private partnership projects. Based on its global green experience, Skanska aims to be the client's first choice for green solutions. The group currently has 58,000 employees in selected home markets in Europe and the US. Skanska's sales in 2014 totaled SEK 145 billion.